Immunostimulants drugs - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.87 [0.77, 0.99]< 131%38 studies (38/-)98.4 %some concerncritical moderatecrucial-
death or transfer to ICU 0.89 [0.56, 1.42]< 142%2 studies (2/-)68.6 %highnot evaluable lowcrucial-
deaths 0.88 [0.79, 0.97]< 129%66 studies (66/-)99.6 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.87 [0.68, 1.11]< 127%11 studies (11/-)87.1 %some concernlow moderatecrucial-
clinical deterioration 0.86 [0.73, 1.00]< 10%9 studies (9/-)97.1 %some concernnot evaluable moderateimportant-
clinical improvement 1.08 [0.97, 1.20]> 132%17 studies (17/-)91.0 %some concernlow moderateimportant-
clinical improvement (14-day) 1.37 [0.69, 2.72]> 156%4 studies (4/-)81.3 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.61 [0.96, 2.70]> 167%6 studies (6/-)96.3 %some concernserious moderateimportant-
clinical improvement (7-day) 1.10 [0.80, 1.51]> 135%4 studies (4/-)72.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.10 [0.96, 1.26]> 128%11 studies (11/-)91.9 %lowcritical highimportant-
death or ventilation 0.94 [0.87, 1.02]< 154%10 studies (10/-)91.7 %some concernlow moderateimportant-
hospital discharge 1.09 [0.99, 1.19]> 148%10 studies (10/-)96.7 %some concernlow moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
mechanical ventilation 0.88 [0.74, 1.04]< 19%14 studies (14/-)93.2 %some concerncritical moderateimportant1
mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 10%2 studies (2/-)55.5 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 2.33 [0.45, 12.00]> 10%1 study (1/-)84.4 %NAnot evaluable important-
Recovery (time to event analysis only) 1.02 [0.81, 1.28]> 10%1 study (1/-)56.7 %NAnot evaluable important-
viral clearance 2.80 [1.05, 7.48]> 187%7 studies (7/-)98.0 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.56 [0.40, 6.09]> 190%2 studies (2/-)73.9 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.37 [0.12, 16.35]> 197%6 studies (6/-)59.8 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.45 [0.97, 2.15]> 166%6 studies (6/-)96.6 %some concernnot evaluable moderateimportant-
ICU admission 0.60 [0.41, 0.88]< 10%7 studies (7/-)99.6 %some concernnot evaluable moderatenon important-
off oxygenation 1.65 [0.05, 50.02]> 181%2 studies (2/-)61.1 %highnot evaluable lownon important-
recovery 1.12 [0.97, 1.28]> 17%4 studies (4/-)94.3 %lownot evaluable highnon important-

safety endpoints 00

composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %NAnot evaluable important-
serious adverse events 1.16 [0.98, 1.36]< 112%10 studies (10/-)3.9 %some concernlow moderateimportant-
superinfection 0.77 [0.06, 9.89]< 176%2 studies (2/-)57.8 %highnot evaluable lowimportant-
adverse events 1.14 [0.92, 1.40]< 10%7 studies (7/-)11.3 %some concernserious moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.